Home » Vertex Hepatitis Drug Beats Forecasts
Vertex Hepatitis Drug Beats Forecasts
Vertex Pharmaceuticals is off to a running start with its new hepatitis C drug. The Cambridge company said had it generated $74.5 million in sales of telaprevir in the quarter that ended June 30.
Boston Globe
Boston Globe
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May